Bone marrow reserve, drug–drug interactions with ART, prophylaxis for mycobacterium, fungal, and viral infections, and the use of granulocyte-colony-stimulating factor when complicated by bone marrow suppression are all considerations in the management of HIV-infected patients with MG. This evidence concerns the gene CSF3 and myasthenia gravis.